Bausch Health Companies Inc. (BHC)
Automate Your Wheel Strategy on BHC
With Tiblio's Option Bot, you can configure your own wheel strategy including BHC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BHC
- Rev/Share 22.2702
- Book/Share 0.9598
- PB -4.628
- Debt/Equity -37.2062
- CurrentRatio 1.3038
- ROIC 0.0515
- MktCap 2612144328.0
- FreeCF/Share 2.9496
- PFCF 2.3877
- PE 7.2233
- Debt/Assets 0.7837
- DivYield 0
- ROE -0.382
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
Read More
Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Bausch (BHC) Upgraded to Buy: Here's Why
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
Published: November 18, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.
Read More
Will Bausch (BHC) Gain on Rising Earnings Estimates?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch Health's Q3 results top expectations as strong Salix and Solta sales fuel growth. Shares gain.
Read More
Bausch Health (BHC) Expected to Beat Earnings Estimates: Should You Buy?
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb
Published: October 20, 2025 by: Benzinga
Sentiment: Positive
Activist investor Jana Partners has reportedly taken a stake in The Cooper Companies (NASDAQ:COO) and is pressing the medical-device maker to evaluate strategic alternatives — including a potential merger between its contact-lens division and Bausch + Lomb (NYSE:BLCO).
Read More
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
Published: September 30, 2025 by: Accesswire
Sentiment: Neutral
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appearance while enhancing natural beauty. LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, a global leader in the medical aesthetics market, will be featured on The Balancing Act, airing on Lifetime, in a special episode spotlighting its portfolio of non-invasive skin rejuvenation and tightening technologies: Thermage® FLX, Clear + Brilliant® and Fraxel FTX™.
Read More
Bausch Health to Announce Third Quarter 2025 Results on October 29
Published: September 30, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will host a live conference call and webcast at 5:00 p.m.
Read More
Bausch Health: Repricing Continues As Deleveraging Gains Traction
Published: September 11, 2025 by: Seeking Alpha
Sentiment: Positive
Bausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, improved profitability, and management's commitment to debt reduction and strategic portfolio development. Despite a heavy debt load, refinancing progress and upgraded 2025 guidance support my thesis of undervaluation and a 27% upside to $9.1 per share.
Read More
Bausch (BHC) Up 21.4% Since Last Earnings Report: Can It Continue?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Read More
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
Published: August 15, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and managed funds have increased their ownership of the Company's common shares. The increase reflects the acquisition by Paulson Capital Inc. and certain affiliates and managed funds of the net long position of 34,721,118 common shares previously held by Mr.
Read More
Why Bausch Health Stock Surged By Nearly 20%
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Positive
Bausch Health surged by nearly 20% on high volume on Monday, rebounding from a post-earnings sell-off driven by high risk and debt concerns. Q2 results beat revenue and GAAP EPS estimates, with strong growth in Xifaxan and Solta Medical, but normalized EPS missed slightly. Debt reduction remains slow, with only $11 million paid down against $14.65 billion net debt.
Read More
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
Read More
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Published: July 29, 2025 by: Benzinga
Sentiment: Positive
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.
Read More
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
Published: July 28, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., has issued an irrevocable notice of redemption pursuant to which it will redeem approximately $602 million of aggregate principal amount of its outstanding 9.25% Senior Notes due 2026, CUSIP Nos. 91911XAV6 and U9098VAN2 (the "Notes"), using cash on hand.
Read More
Five Popular Stocks Insiders Have Been Aggressively Buying
Published: June 24, 2025 by: 24/7 Wall Street
Sentiment: Positive
We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.
Read More
Insiders Make Huge Buys in Gold Miners and More
Published: June 19, 2025 by: 24/7 Wall Street
Sentiment: Neutral
In the past week or so, a couple of gold-mining stocks attracted the attention of insider buyers.
Read More
Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares
Published: June 18, 2025 by: Market Watch
Sentiment: Positive
Bausch Health shares rose Wednesday morning after a director made a substantial purchase of company stocks.
Read More
Why Is Bausch (BHC) Down 13% Since Last Earnings Report?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Read More
Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appearance and the popularity of minimally invasive procedures fuel demand, while the Asia-Pacific region sees rapid expansion due to urbanization and rising incomes. Key players like Allergan and Galderma lead the way. For insights and strategic opportunities, explore historical data and forecasts included in this comprehensive market report. The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by …
Read More
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today's announcement reinforces Bausch + Lomb's commitment to equip cataract surgeons with choices to fit the right lens to the right patient f.
Read More
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected.
Read More
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Bausch Health says Carl Icahn has exposure to about 34% of company's shares
Published: April 22, 2025 by: Reuters
Sentiment: Positive
Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.
Read More
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Bausch + Lomb recalls some of its implantable eye lenses
Published: March 27, 2025 by: Reuters
Sentiment: Negative
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.
Read More
Bausch Health to Announce First Quarter Results on April 30
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Read More
About Bausch Health Companies Inc. (BHC)
- IPO Date 1994-03-29
- Website https://www.bauschhealth.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Thomas J. Appio
- Employees 20700